Each year, the leading innovative pharmaceutical companies around the world lose revenues when the patents on their innovative drugs expire, and generics are allowed to replace them in the market. The table below shows how much money will be lost on currently existing patents by pharma companies around the world, based on current data.
In 2014, Doliprane, Aureomycine, and Microdiol were the top three medicines in Morocco by volume. Click here to read more articles and interviews from Morocco, and to download the latest…
The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker Abbreviated New…
Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural mechanism which is present in living…
In France, the ACOSS (central agency of social security funds) is in charge of the social security general scheme’s cash operations. It manages the The Union of Social Security contribution and…
These ten Chinese pharma companies ranked by 2018 revenues, each brought in more than a billion US dollars. Sinopharm comes out on top with revenues of USD 48.5 billion. Made…
The top 10 of Pharmaceutical Exec’s Top 50 Companies 2020. Roche overtakes Pfizer to take the number one spot, followed by Novartis which moves up from third to second on…
As geopolitical tensions between China and the US increase and pharma industry stakeholders are increasingly looking elsewhere in Asia to diversify their supply chains, Vietnam has emerged as a highly…
Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global…
The COVID-19 pandemic exposed Africa’s dependence on overseas production as vaccines were quickly rolled out in other parts of the world while African countries remained at the bottom of the…
See our Cookie Privacy Policy Here